Drug interactions
Encorafenib + Sorafenib
Severity: Major
Encorafenib and Sorafenib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both agents can prolong the QTc interval, so the combination raises the risk of torsades de pointes. Encorafenib labeling advises monitoring when other QT-prolonging drugs are given.
What this interaction means in plain words
Encorafenib and Sorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Encorafenib belongs to Oncology; Sorafenib belongs to Oncology.
Why it happens
Additive pharmacodynamic QT prolongation.
What to do
Avoid the combination where possible. If used, monitor ECGs and electrolytes and correct hypokalemia and hypomagnesemia.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Sorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Sorafenib
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Sorafenib?
MediHelp rates the interaction as major. Encorafenib and Sorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both agents can prolong the QTc interval, so the combination raises the risk of torsades de pointes. Encorafenib labeling advises monitoring when other QT-prolonging drugs are given.
How serious is the interaction between Encorafenib and Sorafenib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination where possible. If used, monitor ECGs and electrolytes and correct hypokalemia and hypomagnesemia.
What other medicines interact with Sorafenib?
MediHelp also lists interactions of Sorafenib with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Sorafenib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
